



Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Com	nnlete	e or Fax Existing Chart	PRESCRIBER INFORMATION				
Name: DOB:							
Address:City, State, Zip:			State License:				
Phone: Al			—				
Email:							
Gender: M F Weight:			_ _,				
Allergies:			Office Contact:				
INSURANCE INFORMATION –				ance cards (front &	back)		
Primary Insurance:Plan #:							
Group #:							
RX Card (PBM): PCN:							
CLINICAL INFORMATION							
☐ M81.8 Osteoporosis, unspecified ☐ M81.00 Osteoporosis without pathological fracture ☐ Other (specify ICD-10):							
T-Score (If known):							
History of osteoporotic fracture? ☐ Yes ☐ No Skeletal Site (If known):							
Has the patient failed or is unable to tolerate bisphosphonate therapy? \square Yes \square No							
☐ If yes, please explain:							
Does the patient have >1 risk factor for fracture? \square Yes \square No							
☐ If yes, please explain:							
Reason for discontinuing previous os							
Calcium level: Date lab drawn:							
TRIED AND/OR FAILED MEDIC	CATIC	DNS LENGT	TH OF THERAPY	REASON FOR	DISCONTINUATION		
EVENITY® ORDERS							
Prescription type: ☐ New start ☐ Restart ☐ Continued therapy			y Total Doses Received:	Date of Last Ir	njection:		
Medication			Directions		Quantity/Refills		
□ Evenity® (Remoserumah) 10Emg	/1 17	☐ 1 Carton (2 Syrii			☐ 1 Carton (2 Syringes)		
☐ Evenity® (Romosozumab) 105mg/1.17			abdomen, thigh, or upper arm.	nges sequentially) subcutaneously once every			
mL prefilled syringes (two-pack)		month for 12 doses in the	assument, empiry or appearanting		Refills:		
Pre-Medication		Dose/Strength		Directions			
☐ Acetaminophen	□ 50	00mg	☐ Take 1-2 tablets PO prior to infusion or post-infusion as directed				
☐ Diphenhydramine	☐ 25mg IV/PO		☐ Take 1 tablet PO prior to infusion or as directed OR				
	☐ 50mg IV/PO		☐ Inject contents of 1 vial IV prior to infusion or as directed				
☐ Methylprednisolone	☐ 40mg ☐ 125mg		☐ Inject contents of 1 vial IV prior to infusion or as directed				
	56						
-	ı						

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



EVENITY®

Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Please Send a Copy of The Patient's Up-to-Date Clinical Notes

INFUSION REACTION ORDERS

Mild reaction protocol:

☑ Diphenhydramine 25mg IV, one time, for pruritus.

If symptoms worsen, see orders for moderate to severe reactions.

Moderate reaction protocol:

- ☐ Acetaminophen 650mg PO, one time, for pyrexia or rigors
- ☑ Diphenhydramine 50mg IV, one time, for pruritus or urticaria
- ☑ Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms

If symptoms worsen, see interventions for severe reactions

Severe reaction protocol: (Call 911 if initiated):

- ☑ Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)
- ☑ Diphenhydramine 50mg IV,one time, for respiratory symptoms, edema, or anaphylaxis
- ☑ Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
- ☑ Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms
- ☑ Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

FLUSHING & LOCKING ORDERS								
Flushing Protocol (>66lbs/33kg)								
PIV and Midline:		Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:						
☑ 0.9% Sodium Chloride 2-5mL IV flush before a	nd after each infusion	\boxtimes 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw						
Locking Protocol (>66lbs/33kg)								
PIV and Midline: ☑ Heparin Sodium 10 units/mL 1mL IV final	PICC: ☑ Heparin Sodium 10 u	nits/mL 3mL IV final	Implanted Port, Tunneled Catheter, and Non- tunneled Catheter:					
flush post normal saline flush	flush post normal saline flush		☐ Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush					
** May substitute Dextrose 5% in Water, or alternative, for 0.9& Sodium Chloride, when indicated due to incompatibility with medications bring infused								
SIGNATURE								
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral								
x	Date:							
Prescriber Signature								

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.